1000413-84-2

Basic information

• Product Name: 2',6'-diMethyl-4'-(3-(Methylsulfonyl)propoxy)biphenyl-3-carbaldehyde
• Synonyms: 2',6'-diMethyl-4'-(3-(Methylsulfonyl)propoxy)biphenyl-3-carbaldehyde;2',6'-diMethyl-4'-(3-(Methylsulfonyl)propoxy)biphenyl-3-carbaldehyde-5;2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-carbaldehyde
• CAS NO: 1000413-84-2
• Molecular Formula: C₁₉H₂₂O₄S
• Molecular Weight: 346.44058
• Mol File: 1000413-84-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 558.0±50.0 °C(Predicted)
• Appearance: /
• Density: 1.180±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2',6'-diMethyl-4'-(3-(Methylsulfonyl)propoxy)biphenyl-3-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2',6'-diMethyl-4'-(3-(Methylsulfonyl)propoxy)biphenyl-3-carbaldehyde(1000413-84-2)
• EPA Substance Registry System: 2',6'-diMethyl-4'-(3-(Methylsulfonyl)propoxy)biphenyl-3-carbaldehyde(1000413-84-2)

Safety Data

• Hazardous Substances Data: 1000413-84-2(Hazardous Substances Data)

Usage

General Description

2',6'-diMethyl-4'-(3-(Methylsulfonyl)propoxy)biphenyl-3-carbaldehyde is a chemical compound with the molecular formula C21H22O4S. It is a biphenyl derivative with a carbaldehyde functional group and a methylsulfonyl substituent attached to a propoxy group. 2',6'-diMethyl-4'-(3-(Methylsulfonyl)propoxy)biphenyl-3-carbaldehyde is commonly used in organic synthesis as a reagent and intermediate for the production of various pharmaceuticals, agrochemicals, and fine chemicals. It has also been studied for its potential biological activities and has shown to exhibit anti-inflammatory and antioxidant properties. However, it is important to handle this chemical with care and follow proper safety procedures due to its potential health hazards and reactivity.

Upstream product

• 7463-51-6 4-bromo-3,5-dimethylphenol 
• 87199-16-4 3-Formylphenylboronic acid 
• 805250-31-1 4’-hydroxy-2’,6’-dimethyl-3-biphenylcarbaldehyde 
• 1372195-69-1 2-bromo-5-(3-methanesulfonyl-propoxy)-1,3-dimethyl-benzene 
• 263400-88-0 3-(methylsulfonyl)propyl 4-methylbenzenesulfonate 

Downstream Products

• 1000413-85-3 (2’,6’-dimethyl-4’-(3-(methylsulfonyl)propoxy)-[1,1‘-biphenyl]-3-yl)methanol 
• 1000413-72-8 [(3S)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid 
• 1234474-57-7 [(3R)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid 
• 1394138-49-8 3'-(chloromethyl)-2,6-dimethyl-4-(3-(methylsulfonyl)propoxy)-1,1'-biphenyl 
• 1394138-50-1 [6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-1-benzofuran-3-yl]acetic acid 

Relevant articles and documents

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Based on an old phenoxyacetic acid scaffold, CPU014 (compound 14) has been identified as a superior agonist by comprehensive exploration of structure-activity relationship. In vitro toxicity study suggested that CPU014 has lower risk of hepatotoxicity than TAK-875. During acute toxicity study (5–500 mg/kg), a favorable therapeutic window of CPU014 was observed by evaluation of plasma profiles and liver slices. Moreover, CPU014 promotes insulin secretion in a glucose-dependent manner, while no GLP-1 secretion has been enhanced. Other than good pharmacokinetic properties, CPU014 significantly improved glucose tolerance both in normal and diabetic models without the risk of hypoglycemia. These subversive findings provided a safer candidate CPU014, which is currently in preclinical study to assess its potential for the treatment of diabetes.

(S) - 2 - (2,3-dihydrobenzo-furan-3-yl) acetic acid derivatives, its preparation process and its use in medicine

The invention relates to an (S)-2-(2,3-dihydrobenzofuran-3-radical) acetic acid derivative, a preparation method of the derivative, a medicine composition containing the derivative and the application of the derivative serving as a therapeutic agent, particularly GPR40/FFA1, and particularly provides the (S)-2-(2,3-dihydrobenzofuran-3-radical) acetic acid derivative shown in a general formula (I), and pharmaceutically acceptable salts of the derivative or a prodrug of the derivative. The compound is an agonist of a GPR40/FFA1 receptor and has a good preventive and therapeutic effect on lots of GPR40-mediated diseases, especially diabetes mellitus. The invention also provides a preparation method of the compound.

PRODUCTION METHOD OF OPTICALLY ACTIVE DIHYDROBENZOFURAN DERIVATIVE

Provided is a production method of an optically active dihydrobenzofuran derivative. A production method of an optically active form of a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof and the like.